Brief: Vera Therapeutics Announces Positive Origin Phase 3 Data For Atacicept In IGA Nephropathy
06/11/2025 15:49
Nov 6 (Reuters) - Vera Therapeutics Inc VERA.O: VERA THERAPEUTICS ANNOUNCES POSITIVE ORIGIN PHASE 3 DATA FOR ATACICEPT IN IGA NEPHROPATHY PRESENTED AT ASN KIDNEY WEEK 2025 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Source text: ID:nGNX7qxDpr Further company coverage: VERA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vera Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Forgent Power, Vera Bradley, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Wells Fargo
U.S. STOCKS ON THE MOVE-Eli Lilly, Waystar, Sysco
Vera Therapeutics gains after kidney disease drug meets goals in confirmatory trial